Browse Articles

Discover research articles across all indexed journals

Alphavirus M1 disrupts super-enhancer-driven oncogenic transcription via non-structural protein NSP2 in osteosarcoma

Nature Communications Jiajun Zhang, Lifeng Yin, Qianqian Han et al. Jul 01, 2026 DOI: 10.1038/s41467-026-75013-9

Abstract Oncolytic virotherapy has shown promise for various cancers, but its application in osteosarcoma (OS) remains underexplored. This study provides evidence that M1, a natural Getah-like alphavirus, exerts oncolytic activity against OS. We demonstrate that OS cells exhibit heightened sensitivity to M1 infection, with its anti-tumor effects not solely dependent on the canonical ER stress-induced apoptosis. Proteomic and ChIP-seq analyses show the DNA-directed RNA polymerase II subunit RPB1 contributes to oncogenic super-enhancer activity and serves as a direct target of M1-mediated regulation. The oncolytic potency correlated positively with the transcriptional dependency on RPB1 within super-enhancer regions. Mechanistically, the viral non-structural protein NSP2 disrupts super-enhancer activity by recruiting the CUL2-RBX1-ELOC complex, which triggers K63-linked ubiquitination and degradation of RPB1. Together, these findings uncover a previously unrecognized mechanism underlying M1 activity in osteosarcoma, support further preclinical evaluation of M1 in this setting, and identify RPB1 as a candidate biomarker for virotherapy response.

A Physically Grounded Descriptor Decoupling Intrinsic and External Contributions to CO <sub>2</sub> Electroreduction over Single-Atom Catalysts

Journal of the American Chemical Society Yuxiao Meng, Yu Cui, Linfeng Fan et al. Jul 01, 2026 DOI: 10.1021/jacs.6c09762

LLM-impersonated debate contributions are more authentic, relevant and coherent than their original: A representative study using BBC1’s Question Time

PLoS ONE Steffen Herbold, Alexander Trautsch, Zlata Kikteva et al. Jul 01, 2026 DOI: 10.1371/journal.pone.0347757

Generative AI has the potential to pollute the public information sphere with made-up content, posing a significant threat to the cohesion of societies at large. This paper offers the first large-scale and systematic study of how authentic, relevant and coherent impersonated content from Large Language Models (LLMs) is perceived by the general public. Based on a cross-section of British society, we show that LLM-generated responses to questions drawn from a broadcast political debate programme in the UK are judged to be more authentic and relevant than the original responses given by the panel members who were impersonated. We also show that stylistic differences do not influence these judgments, meaning that the distinction of original and generated content is challenging for the general public. Taken together, this means that LLMs can be made to deceive the public regarding the nature of statements in the political domain, with the consequence that there is a dire need to inform the general public of the potential harm this can have on society.

Optimizing cyberattack frequency forecasting by advanced machine learning adaptation with tumbling windows

Scientific Reports Song-Kyoo Kim, Zeqiye Zhan Jul 01, 2026 DOI: 10.1038/s41598-026-59048-y

The structure of the SufBC2D-SufE complex reveals the mechanism of sulfur transfer in bacterial Fe-S cluster assembly

Journal of Biological Chemistry Nidhi Chhikara, Nadia Mireku, Jack A. Dunkle et al. Jul 01, 2026 DOI: 10.1016/j.jbc.2026.113328

Real-world comparison of carboplatin–pemetrexed–bevacizumab versus chemo-immunotherapy in EGFR-mutated lung cancer.

Journal of Clinical Oncology Tadashi Nishimura, Hajime Fujimoto, Hitoshi Sumitani et al. Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.285

285 Background: The optimal treatment strategy following resistance to epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR-TKIs) in patients with EGFR-mutated non–small cell lung cancer (NSCLC) remains controversial. Although the combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) has demonstrated clinical efficacy, real-world comparative data versus carboplatin, pemetrexed, and bevacizumab (CPemB) are limited. Methods: We conducted a multicenter retrospective observational study across eight institutions in Japan between April 2012 and June 2025. Patients with EGFR-mutated NSCLC who developed resistance to EGFR-TKIs and subsequently received either CPemB or ABCP were included. Treatment efficacy, survival outcomes, and adverse events were assessed. To account for baseline imbalances, inverse probability of treatment weighting (IPTW) based on propensity scores was applied. Results: A total of 119 patients were included. The CPemB group comprised 56 patients and the ABCP group comprised 63 patients. The objective response rate was significantly lower in the CPemB group than in the ABCP group (32.1% vs. 57.1%; p = 0.0095). In the unadjusted analysis, median progression-free survival (PFS) was 7.62 months with CPemB and 6.93 months with ABCP, whereas median overall survival (OS) was 17.5 months with CPemB and 14.55 months with ABCP. After IPTW adjustment, no significant differences in PFS or OS were observed, consistent with the unadjusted findings. Distinct safety profiles were identified: thrombocytopenia and hepatic dysfunction occurred more frequently with CPemB, whereas febrile neutropenia, rash, and peripheral neuropathy were more common with ABCP. Conclusions: In patients with EGFR-mutated NSCLC after EGFR-TKI resistance, ABCP achieved a higher objective response rate than CPemB. Survival outcomes were comparable between the two regimens. Given their distinct toxicity profiles, treatment selection should be individualized according to patient characteristics and preferences. Larger prospective studies are warranted to validate these findings.

Acute skin toxicity comparison of adjuvant two-weekly accelerated hypofractionated versus three-weekly moderately hypofractionated radiotherapy in breast cancer: A phase 2, open label, randomized control trial.

Journal of Clinical Oncology Aswathi P. L., Pooja Sethi, Saravanan Kandasamy et al. Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.tps68

TPS68 Background: Moderately hypo-fractionated radiotherapy (40 Gy/15 fractions/3 weeks) is the established adjuvant standard after breast-conserving surgery or mastectomy. Subsequent trials validated further treatment acceleration, consistent with the low α/β ratio (~3 Gy). Indian phase II data using 34 Gy/10 fractions/2 weeks showed acceptable ≥Grade 2 dermatitis; however, no Indian randomized study directly compares this 2-week regimen with contemporary 3-week schedules incorporating regional nodal irradiation and simultaneous integrated boost despite 33% shorter treatment duration. Methods: The study is prospective, non-stratified, randomized phase II, open labelled, enrolls women with histologically confirmed invasive carcinoma (pT0–3, pN0–2a), According to AJCC 8 th edition, following breast-conserving surgery or mastectomy with negative margins. Eligible patients are ≥18 years without advanced loco-regional disease, prior malignancy, distant metastasis, prior thoracic irradiation, indication for internal mammary nodal irradiation or pregnancy. Participants are assigned 1:1 through computer-generated block (size 4 and 6) randomization with allocation concealment. Control arm: moderately hypo-fractionated radiotherapy (40 Gy/15 fractions/3 weeks) with regional nodal irradiation (RNI) as indicated and simultaneous integrated boost (SIB) of 8 Gy in 15 fractions. Interventional arm: accelerated hypo-fractionated radiotherapy (34 Gy/10 fractions/2 weeks) with RNI as indicated and SIB of 8 Gy in 10 fractions. CT simulation with immobilization, ESTRO-guided target delineation, image-guided verification, and protocol-specified organ-at-risk constraints are mandated. The primary endpoint is cumulative ≥Grade 2 acute radiation dermatitis (RTOG; CTCAE v5.0) during treatment and within 3 months. Secondary endpoints include loco-regional control, Quality of life assessment (EORTC c30 and BR45) late toxicity at 6 months (RTOG; CTCAE v5.0), and dosimetric outcomes. Assuming dermatitis rates of 68% versus 32%, 64 patients provide 80% power (two-sided α=0.05); 72 will be enrolled allowing 10% attrition. Statistical analyses for primary outcome will include Chi-square/Fisher’s exact tests, Kaplan–Meier estimates with log-rank comparison, and Cox proportional hazards modelling. Secondary outcome will use Independent T test and chi square or fisher exact test. Accelerated 34 Gy/10 fractions is expected to achieve non-inferior acute toxicity, comparable early loco-regional control, and improved treatment efficiency, supporting its potential adoption in high-volume, resource-constrained oncology settings. Clinical trial information: CTRI/2024/10/074718 .

Two-pore channel-2 controls calmodulin-dependent STIM1 inactivation

Nature Communications Subo Lee, Raphael Néré, Kyoung Sun Park et al. Jul 01, 2026 DOI: 10.1038/s41467-026-75158-7

Abstract Lysosomal two-pore channels (TPC) trigger Ca 2+ release from the endoplasmic reticulum (ER). The ensuing ER Ca 2+ depletion activates STIM1-gated store-operated Ca 2+ entry (SOCE) channels that sustain Ca 2+ signals regulating fundamental cellular processes. How TPC channels and STIM1 integrate distinct intra and extracellular cues is unclear. Here, we show that TPC2 activation inhibits SOCE by enforcing rapid and persistent Ca 2+ -CaM-dependent inactivation of the STIM-Orai activating region (SOAR). The TPC2 activators NAADP and TPC2-A1-N abrogated SOCE in multiple cell lines and enhanced the slow Ca 2+ dependent inactivation (SCDI) of STIM1-gated Orai1 channels. TPC2 engagement triggered lysosomal Ca 2+ release and mobilized ER Ca 2+ stores but prevented RFP-STIM1 recruitment to the TIRF plane by thapsigargin and disassembled RFP-STIM1 clusters forming after store depletion, preventing and acutely reversing SOCE. These effects persisted in STIM1 mutants truncated after the SOAR and were prevented by TPC2 genetic or pharmacological invalidation, Calmodulin (CaM) inhibition, and cytosolic Ca 2+ chelation. We conclude that Ca 2+ ions released by TPC2 channels on lysosomes regulate CaM-dependent STIM1 inactivation.

Precision Oligo(ethylene glycol) Interfaces Shape Nanoparticle Biodistribution through In Vivo Protein Corona

Journal of the American Chemical Society Mingxuan Hou, Minglong Chen, Jie Cen et al. Jul 01, 2026 DOI: 10.1021/jacs.6c06399

Evolutionary lags in the primate brain size/body size relationship revisited

PLoS ONE R. I. M. Dunbar Jul 01, 2026 DOI: 10.1371/journal.pone.0351073

The original brain lag hypothesis proposed that primate brain evolution depended on spare energy derivative of savings of scale enabled by first increasing body size. However, in a seminal analysis, Deaner &amp; Nunn concluded that there was no evidence for a brain lag. I revisit their analysis and show that using statistically more appropriate analyses and updated data yields a significant brain lag effect. However, contrary to the original brain lag hypothesis, the brain/body ratio does not converge back on the allometric regression line, but continues to evolve beyond it. Increases in brain size are correlated with exploiting large group size rather than large body size as the principal defence against predation risk, with significant growth in brain size (but not body size) only being possible if species adopt a more frugivorous diet. I then use these findings to show that hominins followed a similar trajectory from an australopithecine baseline on the relevant allometric regression. In sum, the brain lag effect is much more complicated than the original hypothesis proposed, with a distinctive switch from emphasising body size to brain size (hence group size) as a solution to ecological challenges.

Evaluation of gastroenteritis causative agents in the 0–17 age group using the multiplex PCR method

Scientific Reports Merve Kayabaş Acun, Mustafa Sağlam, Tekin Karslıgil Jul 01, 2026 DOI: 10.1038/s41598-026-59746-7

Rolling Up Transition Metal Chalcogenides/Oxide Heterostructures Enables Polarity‐Tunable and High‐Switchable Memristors

Advanced Materials Xiaofan Wang, Xiaokai Chen, Ruixi Qiao et al. Jul 01, 2026 DOI: 10.1002/adma.202522853

ABSTRACT Harnessing transition metal dichalcogenides (TMDCs) for memristors provides a promising pathway toward high‐density data storage and neuromorphic functionalities. Yet the single operation mode and insufficient on/off ratio extremely restrict the ultimate device performance. Here, we design and construct a high‐order superlattice‐based memristor by rolling up oxide/TMDCs heterostructures, which exhibits tunable resistive switching polarity and a high on/off ratio. Four types of heterostructures are created via fine‐controlled oxygen plasma to in situ oxidize the top few layers into uniform transition metal oxide. Capillary forces in organic reagents are utilized to drive these heterostructures to spontaneously roll up. The as‐formed high‐order oxide/TMDCs superlattices with alternately stacked TMDCs and oxides are clearly resolved by the cross‐section scanning transmission electron microscope and corresponding elemental mappings. With pre‐set oxide layers supplying mobile oxygen atoms, bipolar resistive switching of the high‐order superlattice‐based memristors is realized in vertical tunneling current measurements. In contrast, when the top and bottom electrodes are arranged in an interleaved configuration, the spatial confinement of conductive filaments converts the switching behavior into a unipolar mode. Furthermore, this polarity‐tunable memristor exhibits an outstanding on/off ratio of approximately 10 7 and a robust multilevel resistance performance. Our work opens a new avenue for the fundamental design of high‐performance and multimodal memristors.

Cell-type–specific compartmentalization and function of the glucosinolate-myrosinase system in Arabidopsis thaliana

Journal of Biological Chemistry Shweta Chhajed, Yatendra Singh, Hajra Maqsood et al. Jul 01, 2026 DOI: 10.1016/j.jbc.2026.113202

Perioperative factors associated with adverse outcomes in head and neck cancer surgery with free flap reconstruction: A sub-analysis of the HANCOS trial.

Journal of Clinical Oncology Pushplata Gupta, Akshay Jain, Monika Tak et al. Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.235

235 Background: Head and neck cancer surgeries with free flap reconstruction carry high morbidity, with complication rates of 30–40%. This sub-analysis of the HANCOS prospective study evaluates perioperative factors influencing outcomes, aiming to identify modifiable risk factors and improve surgical benchmarks in this high-risk population. Methods: This prospective observational cohort sub-analysis single-center observational study after institutional ethics committee approval and CTRI reg. CTRI/2025/10/096289 [Registered on: 22/10/2025] Trial Registered Prospectively. Current data consists of 100 adult patients undergoing major HNC surgery with free flap reconstruction. Data collection spanned preoperative, intraoperative, and postoperative phases, focusing on three key outcomes: re-exploration, flap failure, and pulmonary complications. Predictors were analysed using univariate and multivariate logistic regression models to identify independent risk factors. Results: The observed incidence rates were 7.0% for re-exploration, 5.0% for flap failure, and 9.0% for pulmonary complications. Multivariate analysis revealed that longer operative duration was independently associated with re-exploration (OR 1.5 per 60 min; p=0.04). For flap failure, significant independent predictors included hypoalbuminemia (OR 3.1 per 1 g/dL decrease; p=0.03) and greater intraoperative blood loss (OR 1.3 per 100 mL; p=0.04). Pulmonary complications were strongly predicted by higher ARISCAT scores (OR 2.2 per 10 points; p=0.002), pre-existing COPD/asthma (OR 3.8; p=0.03). Conclusion: Adverse outcomes following free flap reconstruction in head and neck cancer surgery are significantly influenced by modifiable perioperative factors. Poor nutritional status, prolonged operative duration, and increased intraoperative blood loss are key determinants of complications, while elevated ARISCAT scores and respiratory comorbidities strongly predict pulmonary events. Targeted preoperative optimization and vigilant intraoperative management may reduce complications and enhance both short-term recovery and long-term outcomes. Conflict of Interest: None declared. Funding: Investigator-initiated study with no external funding. Variable Flap failure (n=5) No failure (n=95) p-value Age (years) 57.6 ± 9.8 51.9 ± 13.0 0.33 Male sex 4 (80.0%) 69 (72.6%) 0.72 BMI (kg/m²) 25.8 ± 5.1 24.3 ± 5.0 0.51 Hb (g%) 11.9 ± 2.4 13.0 ± 2.0 0.22 Serum albumin (g/dL) 3.4 ± 0.4 4.2 ± 0.6 0.003 Platelet count (x10³/µL) 238 ± 102 279 ± 110 0.42 Caprini score 6.2 ± 2.0 5.3 ± 2.0 0.31 Duration of surgery (min) 528 ± 131 418 ± 95 0.01 Blood loss (mL) 1010 ± 440 630 ± 270 0.004

Inetetamab combined with pyrotinib for neoadjuvant treatment of HER2-positive locally advanced breast cancer (neoPICD): A prospective, multicenter, single-arm phase II trial.

Journal of Clinical Oncology Chenghui Yang, Yiying Xu, Ouchen Wang Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.27

27 Background: Neoadjuvant docetaxel plus carboplatin with trastuzumab and pertuzumab (TCbHP) is the standard regimen for HER2-positive breast cancer, yet 22%–25% of patients develop resistance to monoclonal antibody–based anti-HER2 therapy. Inetetamab, an anti-HER2 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity, and pyrotinib, an oral irreversible pan-HER tyrosine kinase inhibitor targeting HER1/2/4, are effective in advanced HER2-positive breast cancer, but their combined neoadjuvant use remains underexplored. We conducted a prospective, single-arm trial (NCT06234137) to evaluate inetetamab, pyrotinib, and chemotherapy in HER2-positive locally advanced breast cancer with high tumor burden. Methods: Patients with non-metastatic, HER2-positive stage II–III primary breast cancer eligible for neoadjuvant therapy were enrolled. The primary endpoint was total pathological complete response (tpCR); secondary endpoints included objective response rate, safety, immunogenicity, and survival outcomes. Sample size was determined using Simon’s two-stage design (null tpCR 45% vs alternative 60%, one-sided α = 0.05, power = 90%). Neoadjuvant therapy comprised inetetamab (8 mg/kg loading then 6 mg/kg IV q3w ×6), pyrotinib (400 mg orally once daily for 18 weeks), and docetaxel (75 mg/m²) plus carboplatin (AUC 6) q3w ×6; treatment continued until completion, progression, or unacceptable toxicity, with surgery 2–4 weeks later and continuation of anti-HER2 therapy to complete one year. Results: Between December 2021 and October 2025, 124 patients were enrolled across seven centers, with 108 evaluable for efficacy. Total pathological complete response (tpCR; ypT0/is, ypN0) occurred in 65 patients (60.2%, 95% CI 50.8–69.6), while breast pathological complete response (bpCR; ypT0/is) was 65.7% (95% CI 56.6–74.8). The objective response rate was 92.6% (95% CI 87.6–97.6), and disease control rate was 100%. Hormone receptor (HR)–negative disease achieved higher tpCR and bpCR rates than HR-positive disease (tpCR: 73.3% vs 43.8%; bpCR: 76.7% vs 52.1%). Multivariate analysis identified HR status as an independent predictor of efficacy (p &lt; 0.05); favorable responses were also associated with premenopausal status, smaller tumor size, earlier nodal stage, lower disease stage, higher Ki-67 index, and higher histological grade. Conclusions: Neoadjuvant inetetamab plus pyrotinib and chemotherapy may provide substantial benefit in HER2-positive locally advanced breast cancer, particularly in HR-negative disease and high proliferative features. Research Sponsor: Special Funding Project for Characteristic Directional S-Disciplines of the First Affiliated Hospital of Wenzhou Medical University (wyyy-2025S01). Clinical trial information: NCT06234137 .

Molecular bridge engineering in covalent organic frameworks for enhanced electronic transport

Nature Communications Seong-Wook Kim, Jeong-Min Seo, Byeongsik Yoon et al. Jul 01, 2026 DOI: 10.1038/s41467-026-75122-5

Visualization of Cu-Cluster-Driven CO <sub>2</sub> Electroreduction by Spatiotemporally Coupled In-Situ Electrochemical Mass Spectrometry

Journal of the American Chemical Society Chengbiao Zhu, Zhangwu Chen, Zimo Zhang et al. Jul 01, 2026 DOI: 10.1021/jacs.6c02004

Damage characteristics and constitutive modeling of coal under real-time temperatures

PLoS ONE Yongjiang Yu, Ning Liu, Guoning Zhang et al. Jul 01, 2026 DOI: 10.1371/journal.pone.0347468

The thermal-mechanical coupling effects induced by thermal injection during coalbed methane extraction can readily lead to coal seam instability. To investigate the influence of real-time temperature on the damage characteristics of coal, uniaxial compression tests were conducted on coal specimens under real-time temperature conditions using the MTS 815 testing system equipped with high-temperature accessories. Combined with the PFC3D discrete element numerical model, a cross-scale analysis was performed to examine the mechanical degradation patterns and fracture evolution characteristics of the coal. Based on a temperature-load coupled damage variable approach, a segmented damage model under combined thermal-mechanical effects was developed. The results show that the peak strain of coal is positively correlated with temperature, whereas compressive strength and elastic modulus exhibit a negative correlation. Thermal damage degree is positively correlated with temperature, with thermal cracks being predominantly tensile. During loading, as temperature increases, the macroscopic failure mode gradually shifts from axial splitting to mixed tensile-shear failure. Microdamage observed in PFC simulations similarly evolves from a predominance of tensile cracks to a mixed pattern, accompanied by a significant increase in the strain range between the initiation point and the peak point, indicating enhanced ductility. To account for the thermal sensitivity and the influence of temperature on failure mechanism, a Gaussian decay function based on a Gaussian kernel function was constructed to reconstruct the post-peak curve of the traditional Weibull model, substantially improving the model’s descriptive capability. The proposed damage constitutive model is applicable to thermomechanically coupled uniaxial compression tests on coal and accurately captures the damage evolution process. The findings provide theoretical support for assessing coal seam stability during thermal injection mining.

BrainPrompting: reconstructing facial memory by brain-based generative AI interaction

Scientific Reports Aotong Li, Tuukka Ruotsalo, Jian Hwee Ang et al. Jul 01, 2026 DOI: 10.1038/s41598-026-59737-8

Balanced Molecular Interactions with Mild Dipole Moment for Intermediate Suppressing in High Performance Antisolvent‐Free Regular <i>α</i> ‐FAPbI <sub>3</sub> Solar Cells

Advanced Materials Long Yao, Haoyu Cai, Yongjun Liu et al. Jul 01, 2026 DOI: 10.1002/adma.73696

ABSTRACT It is promising to fabricate perovskite solar cells (PSCs) without antisolvent, but its intrinsic slow nucleation and unhomogenized growth are often accompanied by enormous solvated intermediates, which divert the α ‐FAPbI 3 crystallization and potentially restrict the acquisition of high‐performance PSCs. Herein, we present a balanced molecular interaction strategy using additives with mild dipole moments of around 1.9 Debye to suppress solvated intermediates. By systematically scrutinizing symmetric dimethyl isophthalate (DMIP) derivatives with varied groups (5‐H, ─F, ─Cl, ─Br, ─NH 2 , ─OCH 3 , and ─OH), the optimum phase‐evolution process is obtained with fluorine substituents. The balanced molecular interactions with Pb 2+ coordination, FA + hydrogen bonding, and I − between solvents and additives, significantly shorten t d‐α (the time for α ‐phase start to dominate) from &gt; 150 to 23 s, enabling the faster and complete phase transformation to high‐quality α ‐FAPbI 3 . Consequently, we obtained a high‐power conversion efficiency up to 26.28%, representing the highest reported efficiency for antisolvent‐free regular PSCs based on pure FAPbI 3 absorbers. Moreover, the device maintains 93.7% of its initial efficiency after 1500 h aging at 85°C and retains 90% after 1000 h maximum power point tracking, demonstrating proper stability through this strategy.